ABSTRACT: Celiac disease (CD) is identified by histopathologic changes in the small intestine which normalize during a gluten-free diet. The histopathologic assessment of duodenal biopsies is usually routine but can be difficult. This study investigated gene expression profiling as a diagnostic tool. A total of 109 genes were selected to reflect alterations in crypt-villi architecture, inflammatory response, and intestinal permeability and were examined for differential expression in normal mucosa compared with CD mucosa in pediatric patients. Biopsies were classified using discriminant analysis of gene expression. Fifty genes were differentially expressed, of which eight (APOC3, CYP3A4, OCLN, MAD2L1, MKI67, CXCL11, IL17A, and CTLA4) discriminated normal mucosa from CD mucosa without classification errors using leave-one-out cross-validation (n ϭ 39) and identified the degree of mucosal damage. Validation using an independent set of biopsies (n ϭ 27) resulted in four discrepant cases. Biopsies from two of these cases showed a patchy distribution of lesions, indicating that discriminant analysis based on single biopsies failed to identify CD mucosa. In the other two cases, serology support class according to discriminant analysis and histologic specimens were judged suboptimal but assessable. Gene expression profiling shows promise as a diagnostic tool and for follow-up of CD, but further evaluation is needed. (Pediatr Res 69: 530-537, 2011) C eliac disease (CD) is an inflammatory condition of the small intestine with a diverse range of symptoms (1), and a prevalence of approximately 1% in Western European populations (2). CD is triggered by gliadin peptides derived from gluten-containing cereals, and the inflamed small intestinal mucosa is characterized by villous atrophy, crypt hyperplasia, and infiltration of lymphocytes in the epithelium (1). In addition, patients with CD have increased permeability over the epithelial layer of the small intestine, and an altered structure of the tight junction has been demonstrated in children with CD (3).
C eliac disease (CD) is an inflammatory condition of the small intestine with a diverse range of symptoms (1) , and a prevalence of approximately 1% in Western European populations (2) . CD is triggered by gliadin peptides derived from gluten-containing cereals, and the inflamed small intestinal mucosa is characterized by villous atrophy, crypt hyperplasia, and infiltration of lymphocytes in the epithelium (1) . In addition, patients with CD have increased permeability over the epithelial layer of the small intestine, and an altered structure of the tight junction has been demonstrated in children with CD (3) .
A positive serological test for antibodies against tissue transglutaminase and/or gliadin may indicate CD (4) . However, a histopathologic assessment (HA) of small intestinal biopsies regarding abnormalities characteristic of CD is required to establish a diagnosis (5, 6) . Diagnostic criteria also require that the patient should have a clinical remission when on a strict gluten-free diet (GFD). The mucosal damage is often graded histologically, using such established measures as the modified Marsh scale (7) . The interobserver reproducibility between pathologists assessing the same small intestinal biopsy specimens shows fair to substantial agreement (8, 9) , with most of the disagreements found in Marsh 1-3B lesions (8) and with some of the interpathologist assessments transgressing the boundary between normal mucosa and CD mucosa (8) .
Gene expression profiling shows a potential as a robust test for classification purposes, with a high interlaboratory reproducibility (10, 11) . A commercial test is already available for inflammatory bowel disease (12) . Genes that display differential expression in CD-damaged mucosa, compared with normal small intestinal mucosa (13, 14) , may prove useful in developing a gene expression-based diagnostic test. Moreover, it might be possible to reveal histological and functional alterations associated with CD by analyzing genes that are differentially expressed along the crypt-villous axis (15, 16) or that may reflect alterations in epithelial permeability associated with CD (17) , or by monitoring genes potentially involved in the intestinal immune response in CD (18) . On the basis of these concepts, we investigate the ability of differential gene expression to classify biopsy specimens using multivariate statistical methods.
MATERIALS AND METHODS
Study subjects. Diagnostic biopsy specimens were collected, after informed and written consent, from pediatric patients investigated for suspected CD. After CD diagnosis, control biopsies were collected on GFD and in some cases after reversion to a gluten-containing diet (diet duration Ͼ9 mo and for the majority Ͼ1 y; Table 1 ). Specimens extracted by using a pediatric Watson capsule were split into two pieces, one for RNA purification and one for HA. Regarding specimens extracted by endoscope, three to four were obtained for HA and one for RNA purification. Specimens for RNA purification were promptly immersed in prechilled RNAlater RNA Stabilization Reagent (Qiagen, Hilden, Germany) and stored at 4°C for approximately 18 h and thereafter at Ϫ20°C awaiting RNA purification. Biopsies were assessed by a single experienced pathologist (I.J.), blinded to the serology and gene expression results, in accordance with instructions for quality assurance and standardization assembled by the Swedish society of pathology. Based on this, a ratio of two was used as a lower boundary for a normal villous/crypt ratio, and for establishing intraepithelial lymphocytosis corresponding to Marsh 1, a count of more than 25 intraepithelial lymphocytes (hematoxylin-eosin stained) per 100 epithelial cells was required. The histological changes were RNA purification and reverse transcription. RNA was purified using the RNeasy Protect Mini Kit (Qiagen) according to the manufacturer's instructions and eluted in a buffer (1 mM Tris-HCl and 0.1 mM EDTA). The concentration and purity of the RNA were determined using Nanodrop ND-1000 (Thermo Fisher Scientific Inc., Waltham, MA), and integrity was assessed using RNA Integrity Number (19) . RNasin Plus RNase Inhibitor (Promega Corporation, Madison, WI) was added to the RNA. One microgram or 2 g of RNA was reverse transcribed in a total volume of 20 or 40 L, respectively, using the High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. The resulting cDNA and the remaining RNA were stored at Ϫ80°C.
Gene expression analysis. Gene expression was analyzed on the 7500 Fast real-time PCR system using Taqman Gene Expression Assays (Table S1 , http://links.lww.com/PDR/A69), Taqman Fast Universal PCR Master Mix, and the recommended Fast Protocol (Applied Biosystems) in a total volume of 15 L. The gene expression analysis was based on reverse transcription replicates from each case. A total of 5 or 10 ng equivalents of cDNA were used per reaction. The work flow was controlled for contamination, and gene expression assays were controlled for amplification of genomic DNA.
Data analysis of gene expression data. Eleven potential reference genes (Human Endogenous Control Plate; Applied Biosystems) were evaluated for low sample-to-sample variation using the GeNorm and NormFinder algorithms in the Genex software (MultiD Analyses, Göteborg, Sweden) and cDNA obtained from reference population biopsies (n ϭ 2) and cases with varying degrees of mucosal damage (n ϭ 4).
Threshold cycle (C T ) values were established using version 1.4 of the 7500 Fast System sequence detection software (Applied Biosystems). The baseline was calculated using data from cycles 3 to 15, and thresholds were adjusted to the log-linear range and set to the same level for all samples within one assay. Missing C T values, due to low copy numbers, were replaced by the highest C T value available for the gene in question, increased by one cycle. The resulting C T values were normalized against the selected reference genes, and the relative expression was determined for each gene in relation to the sample with the lowest expression (2 (C T maxϪC T sample) ) (Genex). Statistical methods. Statistical analysis were performed using Statistica version 9.1 (Statsoft, Tulsa, OK). P values Ͻ0.05 were considered significant (no adjustment for multiple testing). Differential expression was investigated using normalized C T values and Mann-Whitney, and the relation between relative gene expression and Marsh grade was investigated using Spearman rank correlation. Genes with significant differential expression were used for unsupervised grouping by means of hierarchical clustering (unweighted pairgroup average, Euclidian distances) and principal component analysis (PCA). Before discriminant analysis (DA), the predictor variables most strongly related to the dependent variable (disease status) were identified by segmenting the range of values for each predictor (normalized gene expression) into 10 categories and performing Pearson's 2 test of independence. This approach was used to select the 16 best predictors for two groups (Marsh 0 versus Marsh 2-3C) and for three groups (Marsh 0 versus Marsh 2-3B versus Marsh 3C). Using the selected genes as input, the best subsets were selected using a general DA model and either the two-group classification scenario or the three-group classification scenario. Subsets were evaluated using Wilk's lambda, the number of predictors, and representation (villi/crypt, epithelial permeability, and immune response). The classification accuracies of the algorithms were assessed by leave-one-out cross-validation (n ϭ 39) and on an independent set of 27 biopsies.
RESULTS

HA.
Biopsies from a total of 70 cases were available for assessment. Specimens from three cases were judged to be nonassessable. The remaining 67 cases were included in the study (Table 1) . Specimens from 18 of these cases were judged to be suboptimal but assessable, whereas the rest were adequate for assessment. A patchy distribution of mucosal changes was found in cases 17, 22, 61, and 64.
Screening for differentially expressed genes. HPRT1 and PGK1 were identified as suitable reference genes based on low variation (Table S2 , http://links.lww.com/PDR/A69).
From a total of 109 genes (Table S1 , http://links.lww.com/ PDR/A69), 52 were selected for further analysis based on a significant difference in expression in Marsh 3A-3C mucosa (n ϭ 10) compared with Marsh 0 mucosa (reference population, n ϭ 4). Reference biopsies and Marsh 0 control biopsies show evidence of differential expression for eight of these 52 genes (data not shown). Although this observation is of interest for further investigation, we used the HA as a reference and treated all Marsh 0 mucosas as one group in this study.
According to the dataset consisting of cases 1-40 (Table 1) , FGF7 and CDK2 were not differentially expressed [Marsh 0 (n ϭ 15) versus Marsh 2-3C (n ϭ 25)] and were therefore excluded, resulting in a total of 50 genes in the subsequent analyses.
Unsupervised multivariate grouping of study subjects. Relationships among study subjects (Table 1 , cases 1-40) were investigated using PCA. A scatter plot of the first two principal components (PCs) resulted in a separation of cases with histologically normal mucosa (Marsh 0), whereas cases with histopathologic changes showed a gradual transition from Marsh 2 to Marsh 3C (Fig. 1) . However, case 22 (Marsh 3A, Table 1 ) clustered together with Marsh 0 cases. These groupings, based on gene expression data, were confirmed by hierarchical cluster analysis (Fig. 2) . One main cluster harbored all Marsh 0 cases. In addition to the oppositely grouped case 22, this main cluster also contained a case with a Marsh 2 mucosa (Table 1 , case 17). The other main cluster harbored only cases with Marsh 2-3C mucosas and was divided into two subclusters, with the majority of Marsh 3C cases in one of the subclusters (Fig. 2) . By selecting the 12 variables making the largest contribution to PC1 and PC2, respectively, a total of 16 genes were selected (Table 2; top three contributors for each PC illustrated in Fig. 3 ), representing 83% of the variation in PC1 and 86% of the variation in PC2. Using these 16 genes, the general pattern of grouping remained the same (data not shown). According to both PCA and hierarchical clustering, case 22 was positioned in the opposite group compared with its Marsh classification and was therefore excluded from the dataset on which variable selection and discriminant functions were established. Expression characteristics of differentially expressed genes. A reduced gene expression for the villi category was observed with increasing mucosal damage (Fig. 3) . The ratios between the mean relative expression in all Marsh 2-3C (n ϭ 24, excluding case 22) and all Marsh 0 (n ϭ 15) cases for the villi gene category ranged from 0.10 to 0.62, where CYP3A4 (0.10) and APOA1 (0.11) exhibited the largest differences in mean expression. An increased gene expression for the crypt category was observed with increasing Marsh grade (Fig. 3) , except for SEMA3F. For the crypt genes, the Marsh 2-3C/ Marsh 0 ratios ranged from 0.65 to 2.11, where RRM2 (2.11) and MKI67 (1.59) displayed the largest ratios. Among genes related to epithelial permeability, the gene expression decreased with increasing mucosal damage (Fig. 3) . The ratios ranged from 0.59 to 0.80, with the largest difference in mean expression found in CLDN15 (0.59). In the immune-responserelated category, the mean expression ratios ranged from 0.46 to 15.10, and the largest ratios were found for IL17A (15.10), CXCL11 (11.67), and IFNG (8.79) (Fig. 3) . The highest mean expressions were associated with the Marsh 2-3C group for all genes in this category except for IL2, IL18, and TLR3. In the category of other potential marker genes, the ratios ranged from 0.14 to 4.87, with the largest ratios observed for TM4SF4 (0.14) and SELE (4.87).
Variable selection and discriminant analysis. The dependent variable (disease status) was classified into two groups (Marsh 0 versus Marsh 2-3C) or three groups (Marsh 0 versus Marsh 2-3B versus Marsh 3C), and for each of these two classification scenarios, the 16 predictors that related most strongly to disease status were selected (Table 2 ) and combined into a set of 24 genes. Among these 24 genes, the best subsets for DA were identified. Subsets of eight genes were included in the selected classification algorithms for two and for three groups, with the only difference found in the villi genes ( Table 2 ).
These two subsets of genes were investigated using leaveone-out cross-validation on the classification scenario from which the subset originated. In addition, because the two subsets of genes only differed with respect to villi genes with similar expression profiles (Fig. 3) , the gene subset originating from the three-group classification scenario was also investigated in the two-group classification scenario. Using either of the two subsets of genes and leave-one-out cross-validation, the classification of the biopsy left out as either Marsh 0 or Marsh 2-3C was 100% in agreement with the HA for all 39 cases. For the three-group classification scenario, all but one classification agreed with the HA. The discrepant result concerned case 21 (Marsh 3A), which was classified as Marsh 3C by DA. Case 22, which had previously been excluded from the dataset, was classified as Marsh 0.
The performance of the classification algorithm derived from the three-group classification scenario was further investigated using an independent set of biopsies from 27 cases ( Table 1 , cases 41-67). Class according to DA agreed with class according to the HA in 23 of the 27 cases in the two-group classification scenario ( Table 3 ). The four discrepancies concerned case 49 (Marsh 0 according to histopathology), which was classified as Marsh 2-3C by DA, and case 58 (Marsh 2 according to histopathology), case 61 (Marsh 2 according to histopathology), and case 64 (Marsh 3B according to histopathology), which were identified as Marsh 0 by DA. Two additional discrepancies were observed using the three-group classification scenario and concerned case 62 (Marsh 3A according to histopathology) and case 65 (Marsh 3B according to histopathology), which were both classified as Marsh 3C by DA (Table 3) .
DISCUSSION
In this study, we have explored putative gene expression markers suitable for discriminating biopsy specimens extracted from histologically normal small intestinal mucosa from those extracted from a mucosa displaying features characteristic of CD. Our approach identified eight genes that seem to be suitable for discrimination based on gene expression profiling (APOC3, CYP3A4, OCLN, MAD2L1 , MKI67, CXCL11, IL17A, and membrane-bound CTLA4).
High discriminatory power for this gene set was indicated by leave-one-out cross-validation. Validation on an independent set of biopsies resulted in four discrepancies using a classification based on either two or three groups. Two of these four discrepancies concerned cases with a patchy distribution of lesions (cases 61 and 64) in biopsies of adequate quality for HA, indicating that DA based on single biopsies failed to identify CD mucosa. For a fraction of pediatric patients diagnosed with CD, a patchy distribution of mucosal alterations has been described (20) . Serology for case 61 supports the results from histopathology (Table 1) , whereas no serology results are available for case 64. The other two discrepancies involved suboptimal specimens for HA (cases 49 and 58). The serology supports the results from DA in these cases (Table 1 ). An additional two discrepancies (cases 62 and 65) were observed using the three-group classification scenario, one of which involved suboptimal histologic specimens (case 65). Based on the entire dataset (cases 1-67, excluding cases with a patchy mucosa and the Marsh 1 case) and leave-one-out cross-validation, class according to DA agreed with class according to the HA for case 62 (data not shown). However, for case 65, DA still disagreed with class according to the HA. Given these observations, multiple biopsies would probably yield more accurate results with respect to true CD status of the small intestinal mucosa, not only for the HA but also for gene expression profiling.
The posterior probabilities of the single Marsh 1 specimen (Table 3) were strikingly distributed between classes, thus suggesting the possibility of distinct classification.
In the intestine, APOA1 (21), APOA4 (21), APOC3 (22), and CYP3A4 (22) represent genes that are predominantly expressed in villous enterocytes and thus potential markers for villous atrophy. Higher expression levels from these genes were found in Marsh 0 and Marsh 2 mucosa, compared with Marsh 3A-3C mucosa (Fig. 3) , being consistent with the destruction of villi present in Marsh 3 mucosa. Significant decreases in CYP3A4 protein expression have previously been observed in pediatric patients with active CD and in patients subjected to gluten rechallenge (23) . An altered plasma apolipoprotein profile has been observed in children with CD, with normalization on a GFD (24) .
MAD2L1 and MKI67 are preferentially expressed in crypt cells (22) . Marsh 2-3C mucosa (characterized by crypt hyperplasia) exhibited an increased expression of these genes (Fig.  3) . Both the MAD2L1 and the MKI67 proteins have been associated with cell proliferation (25, 26) , and increased histologic staining of MKI67 protein in crypts is a potential marker of CD with minimal morphologic change (27) .
OCLN encodes a transmembrane tight junction protein (occludin) and contributes to the epithelial barrier (17) . Marsh 2-3C mucosa exhibited a decreased expression of this gene (Fig. 3) . On exposure to gliadin, a larger progressive decrease in OCLN expression has been observed in intestinal tissue from patients with CD, compared with controls (28) .
Marsh 2-3C mucosa exhibited an increased level of CXCL11 expression, a result in conformity with previous studies (18) . The CXCL11 encoded chemokine has been re- CXCL11  CXCL11  CYP4F2  IL17A  GZMB  IL17A  IL17A  ENPP3  IL8  IL2  GZMB  LCT  IL8  IFNG †  MAD2L1  MKI67  IL17A  MKI67  OCLN  LCT  OCLN  SEMA3F  NOS2  RRM2  TJP1  TM4SF4  TM4SF4  TM4SF4  TNFRSF9 TNFRSF9 TNFRSF9
Selections for the Pearson's 2 test and the general discriminant models are based on either two groups (Marsh 0 (M0) vs Marsh 2-3C (M2-3C)) or three groups (M0 vs Marsh 2-3B (M2-3B) vs Marsh 3C (M3C)).
* Top three contributors to principal component 1, illustrated in Figure 3 . † Top three contributors to principal component 2, illustrated in Figure 3 .
vealed as a potent antagonist of the CCR3 receptor (29), recently identified as a possible risk factor for CD (30) . IL-17 (encoded by IL17A) has been associated with a number of chronic inflammatory and autoimmune diseases (31) . In line with this study, enhanced IL17A expression has been observed in the intestinal mucosa of patients with CD (32). The protein encoded by CTLA4 exists in a membrane-bound variant and a soluble variant, participates in the regulation of T lymphocytemediated inflammatory responses, and has been genetically linked to CD (33) . Increased levels of soluble CTLA-4 have been detected in serum from patients with active CD, with a decrease on GFD (34) . Transcripts corresponding to both membrane-bound and soluble CTLA-4 show increased expression levels in Marsh 2-3C biopsies ( Fig. 3 ; Table S1 , http://links.lww.com/PDR/A69). The expressions of several of the genes show no distinction between Marsh 3A and Marsh 3B (Fig. 3) . This is particularly interesting because a simplified classification has been proposed, sorting Marsh 3A and 3B into one class and Marsh 1 and Marsh 2 into another class, resulting in an increase in the overall kappa values from 0.35 for the modified Marsh classification to 0.55 for the simplified classification (8) . In this study, we have encountered only a few Marsh 2 mucosas and therefore have chosen to group Marsh 2 together with Marsh 3A-3B.
A simplified classification consisting of fewer grades of mucosal lesion in conjunction with a classification based on a gene expression panel might provide more accurate and reproducible results compared with current practice in diagnosing and monitoring CD. Furthermore, issues related to biopsy orientation could be avoided. Quantitative real-time PCR is a readily accessible technique that can be used to rapidly assess the expression of multiple genes. A classification based on gene expression analysis of three biopsies per patient would entail a laboratory service cost comparable with that of a HA. Although the results of this study emphasize the need for multiple specimens from the small intestine for the evaluation of intestinal damage, we are confident that it is possible to establish DA based on gene expression as a diagnostic tool for CD as well as for monitoring the effects of GFD. However, DA based on the selected genes needs to be further validated. 
